Pioglitazone and bariatric surgery are the most effective treatments for non‐alcoholic steatohepatitis: A hierarchical network meta‐analysis-Reference-Cited by-同舟云学术

Pioglitazone and bariatric surgery are the most effective treatments for non‐alcoholic steatohepatitis: A hierarchical network meta‐analysis

Published:2021-01-15 Issue:4 Volume:23 Page:980-990
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Panunzi Simona¹,Maltese Sabina²,Verrastro Ornella³⁴,Labbate Luca²,De Gaetano Andrea¹,Pompili Maurizio³⁴,Capristo Esmeralda³⁴,Bornstein Stefan R.⁵⁶,Mingrone Geltrude³⁴⁶^ORCID

Affiliation:

1. CNR‐IASI, Laboratorio di Biomatematica, Consiglio Nazionale delle Ricerche, Istituto di Analisi dei Sistemi ed Informatica Rome Italy

2. CNR‐IRIB, Consiglio Nazionale delle Ricerche, Istituto per la Ricerca e l'Innovazione Biomedica Palermo Italy

3. Fondazione Policlinico Universitario A. Gemelli IRCCS Rome Italy

4. Università Cattolica del Sacro Cuore Rome Italy

5. Department of Medicine III Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden Dresden Germany

6. Division of Diabetes and Nutritional Sciences Faculty of Life Sciences and Medicine, King's College London London UK

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14304

Reference36 articles.

1. Non-Alcoholic Steatohepatitis: From Pathophysiology to Novel Therapies

2. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes

3. Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates

4. Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases

5. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. S2k-Leitlinie Klinische Ernährung in der Hepatologie;Aktuelle Ernährungsmedizin;2024-08

2. Treatment of Metabolic (Dysfunction)-Associated Fatty Liver Disease: Evidence from Randomized Controlled Trials—A Short Review;Metabolic Syndrome and Related Disorders;2024-08-01

3. Should the new EASL–EASD–EASO Clinical Practice Guidelines on MASLD recommend pioglitazone as a MASH-targeted pharmacotherapy?;Journal of Hepatology;2024-07

4. 2024 UPDATE: the Brazilian Diabetes Society position on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) in people with prediabetes or type 2 diabetes;Diabetology & Metabolic Syndrome;2024-01-19

5. Metabolische Chirurgie;Adipositas;2024